Drug Trial Radar · NCT06272812
A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5,531
Actual
Start
Feb 19, 2025
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- International AIDS Vaccine InitiativeResearch network
- Sponsor type
- Research network
- Collaborators
- Biofabri, SLU; Universidad de Zaragoza
- First posted
- Feb 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in adolescents and adults aged 14-45 years, living in a TB endemic region.
Conditions
- Tuberculosis (TB)
Interventions
MTBVACBiological
Vaccine Dose: MTBVAC 5x10\^5 Formulation (approximately, per standard dose): 3 - 17x10\^5 CFU Sucrose Sodium glutamate Presentation: Lyophilized pellet in vials (10 doses) Volume: 0.1 mL/dose Intradermal
PlaceboBiological
0.9% saline Volume: 0.1 mL/dose Intradermal
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the protective efficacy of MTBVAC against bacteriologically confirmed PTB, not associated with HIV infection, diagnosed by more than one diagnostic test with sputum obtained before initiation of TB treatment, in baseline IGRA-positives.Time frame: 36 Months
Locations
16 sites in 3 countries. Site status is shown where the registry gives one.
Victoria Biomedical Research Institute
Kisumu, Kenya
Kenya Medical Research Institute
Nairobi, Kenya
JOSHA Research
Bloemfontein, South Africa
South African Tuberculosis Vaccine Initiative
Cape Town, South Africa
TASK Applied Science Pty Ltd. TASK Delft
Cape Town, South Africa
UCTLI CLII - Centre for Lung Infection and Immunity
Cape Town, South Africa
University of Cape Town Lung Institute PtyLtd. Centre for Tuberculosis Research Innovation
Cape Town, South Africa
Wellcome Centre for Infectious Diseases Research in Africa
Cape Town, South Africa
Synergy Biomedical Research Institute
East London, South Africa
TASK Eden Pty Ltd.
George, South Africa
Perinatal HIV Research Unit
Johannesburg, South Africa
Be Part Research Pty Ltd.
Paarl, South Africa
The Aurum Institute Rustenburg Clinical Research Centre
Rustenburg, South Africa
Desmond Tutu Health Foundation, Masiphumelele Research Office
Sunnydale, South Africa
The Aurum Institute Tembisa Clinical Research Centre
Tembisa, South Africa
Ifakara Health Institute
Dar es Salaam, Tanzania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.